TAU-BASED THERAPEUTICS IN ALZHEIMER’S DISEASE: WHERE WE ARE AND WHAT LIES AHEAD
Article Sidebar
Main Article Content
Аннотация:
Alzheimer’s disease (AD) is an age-related neurodegenerative condition clinically defined by progressive memory loss and cognitive impairment. It currently affects over 47 million people worldwide, a figure projected to exceed 131 million by 2050. AD is the leading cause of dementia, accounting for approximately 60–80% of all diagnosed cases. Sporadic Alzheimer’s disease, the most common form, occurs in 10–50% of individuals over the age of 65. Its development is influenced by a wide range of factors, including aging, lifestyle choices (such as diet, exercise, education, and cognitive activity), immune system decline, chronic inflammation, infections (both chronic and latent), vascular dysfunction, and sleep disturbances. Recent findings also suggest a possible link between gut microbiota, ischemic events, and AD pathogenesis.
Article Details
Как цитировать:
Библиографические ссылки:
Yoshiyama Y, Lee VMY, Trojanowski JQ. Therapeutic strategies for tau mediated neurodegeneration. J Neurol Neurosur Psychiat. 2012;84:784–95. [PMC free article] [PubMed] [CrossRef]
Michael MS. Targeting tau protein in Alzheimer’s disease. Lancet. 2016;388:2842–4. [PubMed] [CrossRef]
Lansdall CJ. An effective treatment for Alzheimer’s disease must consider both amyloid and tau. Biosci Horizons. 2014;7:1–11. [CrossRef]
Liu H, Xie A-M, Wang L, Xiang-Qun WS. Advances in recent patent and clinical trial drug development for Alzheimer’s disease. Pharm Pat Anal. 2014;3:429–47. [PMC free article] [PubMed] [CrossRef]
Pluta R, Lossinsky AS, Walski M, Wisniewski HM, Mossakowski MJ. Platelet occlusion phenomenon after short- and long-term survival following complete cerebral ischemia in rats produced by cardiac arrest. J Hirnforsch. 1994;35:463–71. [PubMed]
Wiśniewski HM, Pluta R, Lossinsky AS, Mossakowski MJ. Ultrastructural studies of cerebral vascular spasm after cardiac arrest-related global cerebral ischemia in rats. Acta Neuropathol. 1995;90:432–40. [PubMed] [CrossRef]
Ooms S, Overeem S, Besse K, Rikkert MO, Verbeek M, Claassen JAHR. Effect of 1 night of total sleep deprivation on cerebrospinal fluid β-amyloid 42 in healthy middle-aged men: A randomized clinical trial. JAMA Neurol. 2014;71:971–7. [PubMed] [CrossRef]
Sochocka M, Donskow-Łysoniewska K, Satler Diniz B, Kurpas D, Brzozowska E, Leszek J. The gut microbiome alterations and inflammation-driven pathogenesis of Alzheimer’s disease – a critical review. Mol Neurobiol. 2019;56:1841–51. [PMC free article] [PubMed] [CrossRef]
Pluta R, Ułamek-Kozioł M, Januszewski S, Czuczwar SJ. Gut microbiota and pro/prebiotics in Alzheimer’s disease. Aging (Albany NY). 2020;12:5539–50. [PMC free article] [PubMed] [CrossRef]
Pluta R. Brain ischemia: Alzheimer’s disease mechanisms. New York: Nova Science Publishers, Inc; 2019. p. 311.